Compare Novo Nordisk A/S (NVO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while iShares 1 3 Year Treasury Bond ETF trades at $81.94. The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SHY | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $83.18 |
52-Week Low | $35.29 | $81.77 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.08% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights institutional buying interest amid fluctuating Treasury yields driven by inflation data and geopolitical tensions.
The outlook for SHY is influenced by Federal Reserve policy expectations and inflation trends. Opportunities include its role as a short-duration bond haven during volatility, but risks involve rising yields pressuring prices and macroeconomic uncertainty. Investors should weigh interest rate sensitivity against current institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
